ciclopirox has been researched along with Benign Neoplasms, Brain in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug." | 5.62 | Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling. ( Cai, L; Chen, L; Han, S; Jin, Q; Li, Q; Liu, Y; Lu, B; Lu, J; Shangguan, F; Su, Z; Tian, X; Wang, C; Wang, L; Yu, S; Zheng, W; Zhou, N, 2021) |
| "Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug." | 1.62 | Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling. ( Cai, L; Chen, L; Han, S; Jin, Q; Li, Q; Liu, Y; Lu, B; Lu, J; Shangguan, F; Su, Z; Tian, X; Wang, C; Wang, L; Yu, S; Zheng, W; Zhou, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Yao, Y | 1 |
| Kogiso, M | 1 |
| Zheng, B | 1 |
| Deng, L | 1 |
| Qiu, JJ | 1 |
| Dong, S | 1 |
| Lv, H | 1 |
| Gallo, JM | 1 |
| Li, XN | 1 |
| Song, Y | 1 |
| Su, Z | 1 |
| Han, S | 1 |
| Jin, Q | 1 |
| Zhou, N | 1 |
| Lu, J | 2 |
| Shangguan, F | 1 |
| Yu, S | 1 |
| Liu, Y | 1 |
| Wang, L | 1 |
| Li, Q | 1 |
| Cai, L | 1 |
| Wang, C | 1 |
| Tian, X | 1 |
| Chen, L | 1 |
| Zheng, W | 1 |
| Lu, B | 1 |
2 other studies available for ciclopirox and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2021 |